Clinical Trial Update: S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial S0019 evaluating combination chemotherapy with or without rituximab in relapsed or refractory non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Lymphoma | Phase 3 | Status: TERMINATED